Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT07017790

Amino Acid PET to Assess the Efficacy of IDH Inhibitor Treatments for IDH Mutated Gliomas

Conditions: Glioma

Sex: All

Ages: 18 Years – 90 Years

Healthy volunteers: No

Enrollment: 22

Sponsor: Central Hospital, Nancy, France

Location: CHRU of NANCY Vandœuvre-lès-Nancy

Summary

Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas

Eligibility Criteria

Inclusion Criteria: * Patients who underwent amino acid PET for early assessment of therapeutic response of IDH-mutated gliomas under anti-IDH treatment between February 2022 and November 2024 Exclusion Criteria: * Individuals who have objected to the use of their data

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07017790). StuddyBuddy aggregates publicly available trial information.